For example, the metabolomics analysis on hepatic cancer cells revealed that CD133+ hepatic cancer stem cells produced remarkable and significant amounts of HBP metabolites, such as UDP-GlcNAc, compared with CD133- non-cancer stem cells (Lin et al., 2016). This evidence concerns the gene PROM1 and liver cancer.